Monday, October 2, 2023
Physicians - maximum of 0.25 AMA PRA Category 1 Credit(s)™
ABIM Diplomates - maximum of 0.25 ABIM MOC points
Nurses - 0.25 ANCC Contact Hour(s) (0 contact hours are in the area of pharmacology)
Pharmacists - 0.25 Knowledge-based ACPE (0.025 CEUs)
Physician Assistant - 0.25 AAPA hour(s) of Category I credit
IPCE - 0.25 Interprofessional Continuing Education (IPCE) credit
This activity is intended for primary care clinicians, dermatologists, nurses, physician assistants, nurse practitioners, pharmacists, and other clinicians who care for patients with atopic dermatitis (AD).
The goal of this activity is for members of the healthcare team to be better able to analyze how an Internet-based mindfulness-based stress reduction (MBSR)/mindful self-compassion (MSC) intervention might affect patients with AD.
Upon completion of this activity, participants will:
Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.
Disclosures for additional planners can be found here.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Medscape, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
College of Family Physicians of Canada Mainpro+® participants may claim certified credits for any AMA PRA Category 1 credit(s)™, up to a maximum of 50 credits per five-year cycle. Any additional credits are eligible as non-certified credits. College of Family Physicians of Canada (CFPC) members must log into Mainpro+® to claim this activity.
Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.
Awarded 0.25 contact hour(s) of nursing continuing professional development for RNs and APNs; 0.00 contact hours are in the area of pharmacology.
Medscape designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) (Universal Activity Number: JA0007105-0000-23-234-H01-P).
Medscape, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until 06/23/2024. PAs should only claim credit commensurate with the extent of their participation.
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 6/23/2023
Valid for credit through: 6/23/2024, 11:59 PM EST
processing....
Atopic dermatitis (AD) affects between 15% and 30% of children and 2% to 10% of adults. The authors of the current study describe how, thanks to its high prevalence data, AD is associated with the highest overall population disease burden of all skin diseases, and this burden goes well beyond the skin. A previous cross-sectional study, which was published in the February 2021 issue of Dermatology and Therapy,[1] explored the psychosocial burden of AD.
A total of 1014 patients with AD from Europe completed surveys regarding mental and overall health. The prevalence of sleep, anxiety, and depressive disorders were 61.6%, 52.7%, and 75.8%, respectively. Negative outcomes for these health elements were associated with worse physical and mental function, as well as work impairment and an overall higher number of physician visits; however, they did not significantly affect the rate of hospitalizations in the study cohort.
Mindfulness-based stress reduction (MBSR) and mindful self-compassion (MSC) have employed with success for other chronic disease states, but the evidence for these interventions in AD is lacking. The current randomized trial by Kishimoto and colleagues addresses this issue.
Adding online mindfulness and self-compassion training to usual care may improve quality of life (QOL) in adults with AD, according to results of a small randomized controlled trial in Japan.
"We found that skin disease-specific QOL improved over time with a large effect size," lead study author Sanae Kishimoto, MHS, MPH, of the School of Public Health, Graduate School of Medicine of Kyoto University, Kyoto, Japan, and colleagues wrote in JAMA Dermatology.[2] "These findings suggest that mindfulness and self-compassion training is an effective treatment option for adults with AD."
A Bothersome Disease That Worsens Quality of Life
Atopic dermatitis, a chronic, relapsing, inflammatory, multifactorial skin disease involving intense itching, affects an estimated 15% to 30% of children and 2% to 10% of adults, with the incidence increasing in industrialized countries, the authors stated.
Measured by disability-adjusted life years, AD has the highest disease burden among skin diseases, and people with AD commonly have anxiety, depression, and sleep problems. Treatments include medications, other skin care, and lifestyle changes. New biologics appear to be effective but are expensive and need to be studied for their long-term safety, the authors added.
"Stress can make the skin worse, but at the same time the skin disease and symptoms cause stress," Peter A. Lio, MD, who was not involved in the study, told Medscape Medical News by email. "This vicious cycle contributes greatly to impairing [QOL]."
A Program Focused on Wise, Kind Self Care
In the SMiLE study,[2] the authors recruited adults with moderate to severe AD and Dermatology Life Quality Index (DLQI) score above 6 from dermatology clinics and through online announcements over 1 year, beginning in July 2019.
The mean age of participants was 36.3 ± 10.5 years of age, approximately 80% were women, and their mean AD duration was 26.6 ± 11.7 years. Everyone was allowed to receive usual care during the study, except for dupilumab (a newly marketed drug when the study started), psychotherapy, or other mindfulness training.
The researchers randomly assigned 56 adults to receive mindfulness training in addition to their usual care and 51 to the waitlist plus usual care. Persons in the training group received 8 weekly 90-minute online mindfulness and self-compassion sessions. Each group-based session was conducted at the same time and day of the week and included meditation, informal psychoeducation, inquiry, and a short lecture, along with an optional 1-day silent meditation retreat at week 7 and an optional 2-hour videoconferencing booster session at week 13.
The intervention encouraged a nonjudgmental relationship with stress using mindfulness-based stress reduction (MBSR) and emphasized a compassionate relationship with oneself during suffering using mindful self-compassion (MSC). The program was developed and taught by lead author Kishimoto, an experienced Japanese licensed clinical psychologist who has a history of AD, the paper noted.
At 13 weeks, after completing electronic assessments, patients in the training group showed greater improvement in the DLQI score than patients on the waitlist (between-group difference estimate, −6.34 [95% CI: −8.27, −4.41); P < .001. The standardized effect size (Cohen's d) at 13 weeks was −1.06 (95% CI: −1.39, −0.74).
Patients in the training group also improved more in all secondary outcomes: severity, itch- and scratch-related visual analog scales, self-compassion, mindfulness, psychological symptoms, and adherence to dermatologist-advised treatments.
They were also more likely to follow their dermatologist's medical treatment plans, including moisturizer and topical steroid use.
One serious adverse event, endometrial cancer in 1 patient, was judged to be unrelated to the intervention.
Online Format May Give More Patients Access to Treatment
"With relatively limited data in the literature, this particularly well-done, important study is likely to positively shape thinking around this topic," said Lio, clinical assistant professor of dermatology and pediatrics at Northwestern University Feinberg School of Medicine in Chicago, Illinois. "This study nicely demonstrates that an online approach can be effective.
"In theory, these methods or techniques could democratize treatments like this, and open them up to many more patients," he added.
He would like to see partially or entirely automated apps (free of cost), similar to meditation "apps," to treat patients more cost-effectively.
"However, given that we almost never have all the known variables for a study, we are generally comfortable extrapolating that the intervention would likely be helpful for patients taking dupilumab as well, despite it not being specifically evaluated in that group," he said.
Susan Massick, MD, clinical associate professor of dermatology at The Ohio State University Wexner Medical Center in Columbus, Ohio, advises clinicians to take a multipronged approach to treating the physical and behavioral components of AD and to embrace therapies beyond prescription medications.
"Self-compassion training is another tool in our toolbox toward finding the right fix for our patients," Massick said by email. She was not involved with this research.
"I applaud the focus of this study on behavioral health training as a means toward wellness and improved mindfulness," she added. "I was impressed by the extent to which these simple measures helped improve the quality of life for patients who used the training."
US Patients Can Benefit From These Findings
"My sense is that AD patients the world over have many similar characteristics and concerns, so I would anticipate that the results would be comparable in a US population," Lio said. "Other studies performed in the US also support this line of thinking."
Although the study involved highly motivated patients in Japan, the suffering that patients with AD experience is universal regardless of race or ethnicity, Massick said. "Americans may be even more willing to embrace mindfulness and self-compassion training as a path toward better health and wellness."
The study was funded the Japan Agency for Medical Research and Development and The Mental Health Okamoto Memorial Foundation, the KDDI Foundation, the Pfizer Health Research Foundation, and the Japan Society for the Promotion of Science.
Kishimoto and several co-authors report relevant financial relationships with pharmaceutical companies. Lio reports financial relationships with Sanofi and Regeneron Pharmaceuticals, Inc. Massick reports no relevant financial relationships.
